^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    1d
    Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, Fondazione Ricerca Traslazionale | Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> May 2027 | Trial primary completion date: May 2022 --> May 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=202, Recruiting, Sichuan University | Not yet recruiting --> Recruiting | Phase classification: P3 --> P2
    Enrollment open • Phase classification
    |
    AiRuiLi (adebrelimab)
    1d
    Treatment of non-muscle-invasive bladder cancer (PubMed, Urologie)
    The therapeutic landscape of NMIBC is undergoing rapid evolution. Combination strategies and novel intravesical therapies have the potential to expand the role of BCG to reduce recurrence and progression rates and further establish bladder-preserving treatment paradigms.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Imfinzi (durvalumab) • sasanlimab (PF-06801591)
    1d
    CHESS: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, ETOP IBCSG Partners Foundation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)
    1d
    SKYSCRAPER-11: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=64, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    VENTANA PD-L1 (SP263) Assay
    1d
    DAPPER: Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, University Health Network, Toronto | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • IO biomarker • Pan tumor
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    2d
    Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions. (PubMed, Transl Androl Urol)
    This review integrates findings from key clinical trials evaluating ICIs, such as pembrolizumab and atezolizumab, used alone or alongside BCG, emphasizing their capacity to elicit sustained therapeutic benefits. ICIs represent a promising therapeutic avenue for patients with BCG-unresponsive NMIBC, supporting a shift toward bladder-preserving management strategies. Future research should focus on biomarker-guided patient selection and explore combination regimens to optimize clinical outcomes, thereby informing both clinical practice and investigational priorities.
    Review • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab)
    4d
    IMFINZI-subQ: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=462, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • gemcitabine • SHR-A2102 • AiRuiLi (adebrelimab)
    4d
    Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=29, Recruiting, Tongji Hospital
    New P1/2 trial
    |
    cisplatin • gemcitabine • simvastatin • AiRuiLi (adebrelimab)
    5d
    A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd.
    New P2/3 trial
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin
    5d
    Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen (clinicaltrials.gov)
    P1, N=4, Terminated, Mayo Clinic | Phase classification: P2 --> P1
    Phase classification
    |
    Imfinzi (durvalumab)